Yahoo
    OTC Markets OTCPK - Delayed Quote USD

    Akeso, Inc. (AKESF)

    10.21 -0.79 (-7.18%)
    As of 9:30:29 AM EST. Market Open.
    Loading Chart for AKESF
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Anthropic’s historic IPO; Akeso’s big clinical showing

    Anthropic’s historic IPO; Akeso’s big clinical showing
    Pharma Voice 3d ago
    Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

    Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
    Business Wire 7d ago
    Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium

    Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
    PR Newswire 8d ago
    Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

    Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
    Zacks 12d ago
    Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

    Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
    PR Newswire 12d ago
    Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

    Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
    PR Newswire 14d ago
    Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

    Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
    Business Wire 14d ago
    Will Phase III Colon Cancer Trial Change Akeso Stock Narrative

    Will Phase III Colon Cancer Trial Change Akeso Stock Narrative
    Simply Wall St. 15d ago
    Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?

    Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?
    Simply Wall St. 22d ago
    First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

    First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
    PR Newswire 23d ago
    Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now

    Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now
    BeInCrypto 26d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: